386 related articles for article (PubMed ID: 26359368)
1. NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.
Garcia-Rendueles ME; Ricarte-Filho JC; Untch BR; Landa I; Knauf JA; Voza F; Smith VE; Ganly I; Taylor BS; Persaud Y; Oler G; Fang Y; Jhanwar SC; Viale A; Heguy A; Huberman KH; Giancotti F; Ghossein R; Fagin JA
Cancer Discov; 2015 Nov; 5(11):1178-93. PubMed ID: 26359368
[TBL] [Abstract][Full Text] [Related]
2. Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.
Garcia-Rendueles MER; Krishnamoorthy G; Saqcena M; Acuña-Ruiz A; Revilla G; de Stanchina E; Knauf JA; Lester R; Xu B; Ghossein RA; Fagin JA
Mol Cancer; 2022 Dec; 21(1):213. PubMed ID: 36476495
[TBL] [Abstract][Full Text] [Related]
3. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
4. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor.
Hirokawa Y; Tikoo A; Huynh J; Utermark T; Hanemann CO; Giovannini M; Xiao GH; Testa JR; Wood J; Maruta H
Cancer J; 2004; 10(1):20-6. PubMed ID: 15000491
[TBL] [Abstract][Full Text] [Related]
5. YAP/TAZ Inhibition Induces Metabolic and Signaling Rewiring Resulting in Targetable Vulnerabilities in NF2-Deficient Tumor Cells.
White SM; Avantaggiati ML; Nemazanyy I; Di Poto C; Yang Y; Pende M; Gibney GT; Ressom HW; Field J; Atkins MB; Yi C
Dev Cell; 2019 May; 49(3):425-443.e9. PubMed ID: 31063758
[TBL] [Abstract][Full Text] [Related]
6. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.
Striedinger K; VandenBerg SR; Baia GS; McDermott MW; Gutmann DH; Lal A
Neoplasia; 2008 Nov; 10(11):1204-12. PubMed ID: 18953429
[TBL] [Abstract][Full Text] [Related]
7. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP.
Liu-Chittenden Y; Huang B; Shim JS; Chen Q; Lee SJ; Anders RA; Liu JO; Pan D
Genes Dev; 2012 Jun; 26(12):1300-5. PubMed ID: 22677547
[TBL] [Abstract][Full Text] [Related]
8. Long glucocorticoid-induced leucine zipper regulates human thyroid cancer cell proliferation.
Ayroldi E; Petrillo MG; Marchetti MC; Cannarile L; Ronchetti S; Ricci E; Cari L; Avenia N; Moretti S; Puxeddu E; Riccardi C
Cell Death Dis; 2018 Feb; 9(3):305. PubMed ID: 29467389
[TBL] [Abstract][Full Text] [Related]
9. Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.
Li W; Cooper J; Zhou L; Yang C; Erdjument-Bromage H; Zagzag D; Snuderl M; Ladanyi M; Hanemann CO; Zhou P; Karajannis MA; Giancotti FG
Cancer Cell; 2014 Jul; 26(1):48-60. PubMed ID: 25026211
[TBL] [Abstract][Full Text] [Related]
10. WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice.
Park J; Kim JS; Nahm JH; Kim SK; Lee DH; Lim DS
Mol Cells; 2020 May; 43(5):491-499. PubMed ID: 32451369
[TBL] [Abstract][Full Text] [Related]
11. MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
Knippler CM; Saji M; Rajan N; Porter K; La Perle KMD; Ringel MD
Endocr Relat Cancer; 2019 Aug; 26(8):699-712. PubMed ID: 31146260
[TBL] [Abstract][Full Text] [Related]
12. YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.
Coggins GE; Farrel A; Rathi KS; Hayes CM; Scolaro L; Rokita JL; Maris JM
Cancer Res; 2019 Dec; 79(24):6204-6214. PubMed ID: 31672841
[TBL] [Abstract][Full Text] [Related]
13. PEA3 sites within the progression elevated gene-3 (PEG-3) promoter and mitogen-activated protein kinase contribute to differential PEG-3 expression in Ha-ras and v-raf oncogene transformed rat embryo cells.
Su Z; Shi Y; Friedman R; Qiao L; McKinstry R; Hinman D; Dent P; Fisher PB
Nucleic Acids Res; 2001 Apr; 29(8):1661-71. PubMed ID: 11292838
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase.
Serrano I; McDonald PC; Lock F; Muller WJ; Dedhar S
Nat Commun; 2013; 4():2976. PubMed ID: 24356468
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
Hyun J; Al Abo M; Dutta RK; Oh SH; Xiang K; Zhou X; Maeso-Díaz R; Caffrey R; Sanyal AJ; Freedman JA; Patierno SR; Moylan CA; Abdelmalek MF; Diehl AM
J Hepatol; 2021 Sep; 75(3):623-633. PubMed ID: 33964370
[TBL] [Abstract][Full Text] [Related]
16. SOX13/TRIM11/YAP axis promotes the proliferation, migration and chemoresistance of anaplastic thyroid cancer.
Tang J; Tian Z; Liao X; Wu G
Int J Biol Sci; 2021; 17(2):417-429. PubMed ID: 33613102
[TBL] [Abstract][Full Text] [Related]
17. Molecular alterations of the NF2 gene in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Zhang N; Zhao Z; Long J; Li H; Zhang B; Chen G; Li X; Lv T; Zhang W; Ou X; Xu A; Huang J
Oncol Rep; 2017 Dec; 38(6):3650-3658. PubMed ID: 29130106
[TBL] [Abstract][Full Text] [Related]
18. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes.
Mizuno T; Murakami H; Fujii M; Ishiguro F; Tanaka I; Kondo Y; Akatsuka S; Toyokuni S; Yokoi K; Osada H; Sekido Y
Oncogene; 2012 Dec; 31(49):5117-22. PubMed ID: 22286761
[TBL] [Abstract][Full Text] [Related]
19. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals.
Zhang N; Bai H; David KK; Dong J; Zheng Y; Cai J; Giovannini M; Liu P; Anders RA; Pan D
Dev Cell; 2010 Jul; 19(1):27-38. PubMed ID: 20643348
[TBL] [Abstract][Full Text] [Related]
20. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.
Beadnell TC; Mishall KM; Zhou Q; Riffert SM; Wuensch KE; Kessler BE; Corpuz ML; Jing X; Kim J; Wang G; Tan AC; Schweppe RE
Mol Cancer Ther; 2016 Aug; 15(8):1952-63. PubMed ID: 27222538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
